An Inflammation-Index Signature Predicts Prognosis of Patients with Intrahepatic Cholangiocarcinoma After Curative Resection

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21(5):594–599. doi:10.1634/theoncologist.2015-0446
   PubMed Web of Science ®Google Scholar
• Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261–280.
   PubMed Web of Science ®Google Scholar
• Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149(6):565–574. doi:10.1001/jamasurg.2013.5137
   PubMed Web of Science ®Google Scholar
• Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 2000;31(4):840–845. doi:10.1053/he.2000.5628
   PubMedGoogle Scholar
• Adhoute X, Penaranda G, Raoul JL, et al. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol. 2016;8(17):703–715. doi:10.4254/wjh.v8.i17.703
   PubMedGoogle Scholar
• Edge SB, Byrd DR, Comptom CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
   Google Scholar
• Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073–1081. doi:10.1093/carcin/bgp127
   PubMed Web of Science ®Google Scholar
• Zhang H, Ren D, Jin X, Wu H. The prognostic value of modified Glasgow prognostic score in pancreatic cancer: a meta-analysis. Cancer Cell Int. 2020;20(1):462. doi:10.1186/s12935-020-01558-4
   PubMed Web of Science ®Google Scholar
• Sun S, He C, Wang J, Huang X, Wu J, Li S. The prognostic significance of inflammation-based scores in patients with ampullary carcinoma after pancreaticoduodenectomy. BMC Cancer. 2020;20(1):981. doi:10.1186/s12885-020-07482-0
   PubMed Web of Science ®Google Scholar
• Han D, Zhang J, Zhao J, et al. Platelet-to-lymphocyte ratio is an independent predictor of chemoradiotherapy-related esophageal fistula in esophageal cancer patients. Ann Transl Med. 2020;8(18):1163. doi:10.21037/atm-20-4053
   PubMed Web of Science ®Google Scholar
• Salcedo MP, Sood AK, Dos Reis R, et al. Perineural invasion (PNI) in vulvar carcinoma: a review of 421 cases. Gynecol Oncol. 2019;152(1):101–105. doi:10.1016/j.ygyno.2018.10.035
   PubMed Web of Science ®Google Scholar
• He C, Huang X, Zhang Y, et al. Signature for predicting recurrence risk of pancreatic ductal adenocarcinoma after radical resection. Front Oncol. 2019;9:1197. doi:10.3389/fonc.2019.01197
   PubMed Web of Science ®Google Scholar
• de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29(23):3140–3145. doi:10.1200/JCO.2011.35.6519
   PubMed Web of Science ®Google Scholar
• Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–387. doi:10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23(13):2109–2123. doi:10.1002/sim.1802
   PubMed Web of Science ®Google Scholar
• He CB, Lao XM, Lin XJ. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study. Chin J Cancer. 2017;36(1):59. doi:10.1186/s40880-017-0227-2
   PubMedGoogle Scholar
• Tang Z, Liu WR, Zhou PY, et al. Prognostic value and predication model of microvascular invasion in patients with intrahepatic cholangiocarcinoma. J Cancer. 2019;10(22):5575–5584. doi:10.7150/jca.32199
   PubMed Web of Science ®Google Scholar
• Jayaramayya K, Balachandar V, Santhy KS. Ampullary carcinoma-a genetic perspective. Mutat Res. 2018;776:10–22.
   Web of Science ®Google Scholar
• Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045–2055. doi:10.1002/hep.26565
   PubMed Web of Science ®Google Scholar
• Branchi V, Jürgensen B, Esser L, et al. Tumor infiltrating neutrophils are frequently found in adenocarcinomas of the biliary tract and their precursor lesions with possible impact on prognosis. J Pers Med. 2021;11(3):233. doi:10.3390/jpm11030233
   PubMed Web of Science ®Google Scholar
• Høgdall D, O’Rourke CJ, Dehlendorff C, et al. Serum IL6 as a prognostic biomarker and IL6R as a therapeutic target in biliary tract cancers. Clin Cancer Res. 2020;26(21):5655–5667. doi:10.1158/1078-0432.CCR-19-2700
   PubMed Web of Science ®Google Scholar
• McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007;22(8):881–886. doi:10.1007/s00384-006-0259-6
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–1812. doi:10.1172/JCI200318921
   PubMed Web of Science ®Google Scholar
• Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454(7203):428–435. doi:10.1038/nature07201
   PubMed Web of Science ®Google Scholar
• Li Y, Wang JS, Guo Y, Zhang T, Li LP. Use of the alkaline phosphatase to prealbumin ratio as an independent predictive factor for the prognosis of gastric cancer. World J Gastroenterol. 2020;26(44):6963–6978. doi:10.3748/wjg.v26.i44.6963
   PubMed Web of Science ®Google Scholar
• Liu X, Hou Y, Wang X, et al. Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer. Hepatol Int. 2020;14(4):567–576. doi:10.1007/s12072-020-10046-w
   PubMed Web of Science ®Google Scholar
• Kemik O, Kemik AS, Begenik H, et al. The relationship among acute-phase response proteins, cytokines, and hormones in various gastrointestinal cancer types patients with cachectic. Hum Exp Toxicol. 2012;31(2):117–125. doi:10.1177/0960327111417271
   PubMed Web of Science ®Google Scholar
• Reynés G, Vila V, Martín M, et al. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol. 2011;102(1):35–41. doi:10.1007/s11060-010-0290-x
   PubMed Web of Science ®Google Scholar
• McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 2001;41(1–2):64–69. doi:10.1080/01635581.2001.9680613
   PubMed Web of Science ®Google Scholar
• Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171–186. doi:10.1097/PSY.0b013e3181907c1b
   PubMed Web of Science ®Google Scholar
• Tong T, Guan Y, Xiong H, Wang L, Pang J. A meta-analysis of Glasgow prognostic score and modified Glasgow prognostic score as biomarkers for predicting survival outcome in renal cell carcinoma. Front Oncol. 2020;10:1541. doi:10.3389/fonc.2020.01541
   PubMed Web of Science ®Google Scholar
• Fujiwara R, Takemura K, Fujiwara M, et al. Modified Glasgow prognostic score as a predictor of prognosis in metastatic renal cell carcinoma treated with nivolumab. Clin Genitourin Cancer. 2020. doi:10.1016/j.clgc.2020.10.007
   Web of Science ®Google Scholar
• He C, Zhang Y, Song Y, et al. Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma. J Cancer. 2018;9(17):3117–3128. doi:10.7150/jca.25339
   PubMed Web of Science ®Google Scholar
• Yoo T, Park SJ, Han SS, et al. Postoperative CA19-9 change is a useful predictor of intrahepatic cholangiocarcinoma survival following liver resection. Dis Markers. 2015;2015:298985. doi:10.1155/2015/298985
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Itoh S, Yoshizumi T, et al. C-reactive protein: albumin ratio in patients with resectable intrahepatic cholangiocarcinoma. BJS Open. 2020;4(6):1146–1152. doi:10.1002/bjs5.50348
   PubMed Web of Science ®Google Scholar
• Lu LH, Zhong C, Wei W, et al. Lymphocyte-C-reactive protein ratio as a novel prognostic index in intrahepatic cholangiocarcinoma: a multicentre cohort study. Liver Int. 2021;41(2):378–387. doi:10.1111/liv.14567
   PubMed Web of Science ®Google Scholar